Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
97.1 rhumatos / 100 000 hab. — département bien doté
8 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
3
3 articles ont été cités au moins 3fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
51
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
10
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
2
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier Départemental Vendée
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Evaluating Treatment Preferences and the Efficacy of Capsaicin 179 mg Patch vs. Pregabalin in a Randomized Trial for Postsurgical Neuropathic Pain in Breast Cancer: CAPTRANE
2025ArticleCancers
Ketamine in chronic pain: A Delphi survey
2022ArticleEuropean Journal of Pain
First Evaluation Switching From Ropivacaine to Highly Concentrated Bupivacaine in Intrathecal Mixtures for Cancer Pain
2021ArticleNeuromodulation
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHD SITE LA ROCHE SUR YON
LES OUDAIRIES BD STEPHANE MOREAU, 85925 LA ROCHE SUR YON CEDEX 9
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of pain research · 2022
European journal of pain (London, England) · 2022
AbstractBackgroundThere is no recommendation in Europe for the use of ketamine in patients with chronic pain. The heterogeneity of practice highlights the need to seek the advice of experts in order to establish a national consensus. This Delphi survey aimed to reach a national consensus on the use of ketamine in chronic pain in Pain clinics.MethodsA collaborative four‐round internet‐based questionnaire was used. It was created after literature search on ketamine administration in chronic pain and included about 96 items. It discussed utility and advantages, adverse events and deleterious aspects, methods of administration, concomitant treatments and assessment of results.ResultsTwenty‐eight experts completed all rounds of the survey with a total of 81.3% items reaching a consensual answer. Neuropathic pain represents the first indication to use ketamine, followed, with a good to moderate utility, by other situations (fibromyalgia, complex regional pain syndrome, central neuropathic pain, peripheral neuropathic pain, nociceptive pain, sensitization, opioid withdrawal, palliative care, depression). Experts agreed on the rare occurrence of adverse events. Concerning routes of administration, intravenous infusion with doses of 0.5–0.9 mg/kg/d for 4 days of treatment is preferred. Place of care is hospital, as in‐ or out‐patient, with a quarterly administration of ketamine. Finally, ketamine effectiveness is assessed 1 month after infusion, and experts encourage combination with non‐pharmacological treatment.ConclusionsThis Delphi survey established a consensus of pain specialists on the use of ketamine in refractory chronic pain, thus providing a basis for future comparative trials.SignificanceThis Delphi survey in chronic pain reached agreement on four main aspects: (1) Priority to treat neuropathic pain with evaluation of effectiveness at 1 month; (2) No deleterious effects in the majority of listed diseases/situations with the absence or <3% of suggested adverse events; (3) 0.5–0.9 mg/kg/d IV infusion; (4) Combination with non‐pharmacological treatment.
Regional anesthesia and pain medicine · 2024
Background Intrathecal analgesia plays a key role for patients suffering refractory cancer pain. Nevertheless, intrathecal drug delivery systems (IDDS), requiring a cervical catheter tip implantation, have been poorly described in medical literature. Aims A monocentric retrospective follow-up study was designed to evaluate results of cervical IDDS for cancer pain. Patients and methods From January 2010 to December 2022, all intrathecal-treated patients were prescribed a combined intrathecal analgesics regimen through a catheter placed in the cervical vertebral canal. Post-implant assessment of pain was determined using a numeric rating scale (NRS). Patients were followed via day-hospital visits and telephone calls at least monthly. Pain scores were compared using the Wilcoxon’s signed rank test. Results Ninety-eight patients were included in this study; all received intrathecal treatments. Implanted patients suffered from severe pain (mean presurgical maximum numerical rating score 8.02±0.24 despite a mean 562.56±127.72 mg of oral morphine equivalent daily dose). Mean survival time after intrathecal treatment start was 208.48±67 days. Intrathecal drug delivery systems provided pain relief compared with initial pain score with a significant statistical difference after 1 week, 1 month, 2 and 3 months (p<0.01). A 50% reduction in initial pain level was achieved in 93% of cases during the first week of intrathecal implant. Conclusions Results suggest that long-term intrathecal treatment using a multidrug regimen for cancer-related pain through cervical intrathecal catheters was suitable and safe in our study population. We demonstrated a clinically and statistically significant pain reduction in patients using mainly a percutaneous lumbar approach.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of clinical medicine · 2026 · Journal Article
Ravaillault S, Alipour H, Leger F, Labarre J, et al.
Pain management nursing : official journal of the American Society of Pain Management Nurses · 2025 · Journal Article
Tailliez N, Planche L, Dorion A, Kacki N, et al.
Cancers · 2025 · Journal Article
Dupoiron D, Bienfait F, Seegers V, Piloquet FX, et al.
Trials · 2020 · Clinical Trial Protocol
Rulleau T, Planche L, Etcheverrigaray F, Dorion A, et al.
Regional anesthesia and pain medicine · 2024 · Journal Article
Dupoiron D, Bienfait F, Carvajal G, Seegers V, et al.
European journal of pain (London, England) · 2022 · Journal Article
Voute M, Riant T, Amodéo JM, André G, et al.
Trials · 2020 · Clinical Trial Protocol
Rulleau T, Planche L, Etcheverrigaray F, Dorion A, et al.
Trials · 2020 · Clinical Trial Protocol
Rulleau T, Planche L, Etcheverrigaray F, Dorion A, et al.
Journal of pain research · 2022 · Journal Article
Dupoiron D, Jubier-Hamon S, Seegers V, Bienfait F, et al.